Brief: Arovella Therapeutics Says FY Net Loss Attributable A$10.2 Mln
31/08/2023 03:09
Aug 31 (Reuters) - Arovella Therapeutics Ltd ALA.AX :
* FY NET LOSS ATTRIBUTABLE A$10.2 MILLION
Source text for Eikon: ID:nASX982LjW
Further company coverage: ALA.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arovella Therapeutics
See all newsBrief: Arovella Therapeutics Appoints Acting CEO
Brief: Arovella Therapeutics Says Michael Baker Resigns As CEO
Brief: Arovella Therapeutics Says Elizabeth Stoner Will Be Retiring As Interim Chair
Brief: Arovella Therapeutics Says IND For Ala-101 Accepted By FDA
Brief: Arovella Therapeutics Appoints Lachie Mallia As CFO